Guest View
User: Pass: | become a member
Archive for the ‘Benzinga’ Category

Benzinga’s M&A Chatter for Wednesday July 9, 2014

Courtesy of Benzinga.

The following are the M&A deals, rumors and chatter circulating on Wall Street for Wednesday July 9, 2014:

Google Rumored to Have Interest in Deal for Time Warner

The Rumor:
Shares of Time Warner (NYSE: TWX) surged higher Tuesday, following a tweet from Fox Business’ Charlie Gasparino, that he has been hearing chatter of a potential bid from Google (NASDAQ: GOOG). Time Warner shares hit a high of $73.07.

Wall Street Journal reporter Doug MacMillan later tweeted that Time Warner’s CEO said his company was not in talks with Google.

Time Warner shares closed off the highs Wednesday at $72.41, a gain of more than 2%.

Hearing Potential Bid for GameStop

The Rumor:
Shares of GameStop (NYSE: GME) spiked higher Wednesday, on renewed unconfirmed market chatter of a potential bid from an unnamed suitor. Chatter had surfaced on June 22 that GameStop had hired an advisor to help it to review strategic alternatives.

A spokesperson for GameStop was unavailable for comment.

GameStop shares closed Wednesday at $41.79, a gain of $0.15.

AbbVie Forced to Retract Comments Regarding Shire Takeover Attempt

The Withdrawn Comments:
AbbVie (NYSE: ABBV) CEO Richard Gonzalez was forced to withdraw comments he made regarding shareholder support for his company’s bid for Shire (NASDAQ: SHPG). The comments were a violation of UK Takeover Panel rules, as the support was not in writing.

AbbVie confirmed today, it had not received commitments of support in writing.

Shire closed Wednesday at $235.08, a gain of almost 1%, while AbbVie lost more than 1% to close at $55.01.

Shareholders Urge Allergan to Make Acquisitions

The CEO Comments:
Allergan (NYSE: AGN) shareholders are encouraging the company to make a large acquisition in order to fight off a $53 billion hostile takeover bid from Valeant Pharmaceuticals (NYSE: VRX) and investor Bill Ackman of Pershing Square, according to a report from Financial Times. Allergan CEO David Pyott, said his company should act quickly in making an acquisition, based on comments from shareholders.

Allergan’s board rejected Valeant’s latest bid of $53 billion in cash and Valeant shares on June 23.

Allergan closed Wednesday at $165.20, a loss of $0.87, while Valeant lost 1% to close at $120.94.

Posted-In: News Hedge Funds Rumors Movers & Shakers Management Insider Trades Movers General





Stocks To Watch For July 3, 2014

Courtesy of Benzinga.

Related SNX
IBM Beats on Earnings, Revenues; Positive Outlook for 2H
Synnex Q2 2014 Earnings Follow Up

Related ISCA
Morning Market Movers
UPDATE: International Speedway Posts Upbeat FQ2 Earnings
International Speedway Up on Strong 2Q Revenue (Fox Business)

Some of the stocks that may grab investor focus today are:

Synnex (NYSE: SNX) reported better-than-expected results for the second quarter. However, the company issued downbeat outlook for the third quarter. It expected adjusted earnings of $1.45 to $1.50 per share on revenue of $3.3 billion to $3.4 billion. Analysts were projecting earnings of $1.53 per share on revenue of $3.29 billion. Synnex shares fell 2.73% to $71.91 in the after-hours trading session.

Wall Street expects International Speedway (NASDAQ: ISCA) to report its Q2 earnings at $0.49 per share on revenue of $186.34 million. International Speedway shares gained 1.02% to close at $33.56 yesterday.

Chesapeake Utilities (NYSE: CPK) announced a three-for-two stock split of its outstanding common stock. Chesapeake Utilities shares fell 2.18% to close at $70.91 yesterday.

QLogic (NASDAQ: QLGC) appointed Tony Carrozza as the senior vice president of worldwide sales. The company also announced its plans to report its FQ1 results after the closing bell on July 24, 2014. QLogic shares declined 0.10% to close at $10.24 yesterday.

Shares of GoPro (NASDAQ: GPRO) tumbled 13.85% in regular trading session on Wednesday after strong gains following its IPO. GoPro shares slipped 0.33% to $41.90 in after-hours trading.

Posted-In: Earnings News Guidance Management Stock Split Pre-Market Outlook Markets Trading Ideas





Apache Says Reviewing Mineral Interest Position -Reuters

Courtesy of Benzinga.

Related APA
Earnings Season Boosts Confidence; S&P Trades At Record Highs
Bank Of America Suggests 'Not Chasing Move' On Apache Activist Investor
Energy Stocks Move Higher as Oil Spikes (Fox Business)

Apache (NYSE: APA) said it is reviewing its mineral interest position to determine the best way to maximize value, according to Reuters. Apache and other energy companies are facing pressure from investors to squeeze more profits from their interests.

View article http://www.reuters.com/article/2014/07/23/us-apache-mineralrights-idUSKB…

Posted-In: ReutersNews Asset Sales





Camtek Up 18% After Q2 Beat; Makes Bullish Remark On Pending Product

Courtesy of Benzinga.

Related CAMT
Morning Market Movers
Benzinga's Top #PreMarket Gainers

Camtek LTD. (NASDAQ: CAMT) shares gained 18 percent Tuesday after posting second-quarter profits that were double Wall Street views.

Israeli-based Camtek, which makes automation equipment for electronics manufacturing and packaging, also told investors that its technology testing for a key pending product called Griphon bolsters confidence that the product will soon launch and start producing revenue in 2015.

Griphon, a 3D inkjet product for computer chip solder mask manufacturing, "will be the dominant technology in the printed circuit board industry for years to come," Chief Executive Rafi Amit said in a statement.

The company posted second-quarter earnings of $0.08 per share on revenue of $23.2 million. Year-earlier earnings were $0.01 on revenue of $22 million. Analysts expected earnings of $0.04 on revenue of $23.5 million.

Small-cap Camtek is frequently volatile. For example, shares soared as much as 57 percent in a single day earlier this month on news of a product launch.

The company has also been something of a favorite of short sellers, with 1.4 million of its 30.5 million shares held as short interest earlier this year. That number has since declined, however, to about a half-million shares.

Camtek traded recently at $4.08, up 18.9 percent.

Posted-In: Earnings News Guidance Hot





Report: IBM Rejects Offer For Chip Operations

Courtesy of Benzinga.

Related IBM
Blackberry Attempts To Rebound From IBM/Apple Deal
The 10 Most-Respected Corporate Brands
Can the iRally Endure? (Fox Business)

International Business Machines (NYSE: IBM) rejected an offer for part of its semiconductor manufacturing operations, according to unnamed sources cited by Bloomberg news service.

An offer from Globalfoundries, owned by government of Abu Dhabi and based in California, was refused by IBM because it was too low, Bloomberg said.

Similar rumors were circulated June 15 when a union seeking to represent IBM workers in New York claimed that IBM's Vice President of Microelectronics had told managers the deal had collapsed.

Bloomberg said Globalfoundries wanted to acquire IBM's engineers and intellectual property, and places no value on its manufacturing plants, which it believes are outdated.

IBM said recently it will participate in a plan by New York State to form a chip development consortium to include General Electric, Lockheed Martin, Endicott Interconnect and several universities. The state will spend $135 million, while companies will spend $365 million over five years on the project.

IBM didn't describe its potential role in the consortium.

IBM traded recently at $194.31, down 0.48 percent.

Posted-In: News Rumors





Markets Tumble; Dollar Tree To Acquire Family Dollar For $8.5 Billion

Courtesy of Benzinga.

Related BZSUM
Tyson Foods Sells Part Of Its Chicken Business; Dollar Tree Buys Family Dollar
Trulia Jumps On Acquisition News; Armstrong World Shares Slide

Following the market opening Monday, the Dow traded down 0.37 percent to 16,897.57 while the NASDAQ tumbled 0.44 percent to 4,429.79. The S&P also fell, dropping 0.41 percent to 1,970.23.

Leading and Lagging Sectors

Utilities shares surged 0.63 percent in trading on Monday. Meanwhile, top gainers in the sector included Korea Electric Power (NYSE: KEP), up 6.7 percent, and Calpine (NYSE: CPN), up 2 percent.

In trading on Monday, non-cyclical consumer goods & services shares were relative laggards, down on the day by about 0.52 percent. Top decliners in the sector included Cal-Maine Foods (NASDAQ: CALM), down 6.5 percent, and Omega Protein (NYSE: OME), off 3.4 percent.

Top Headline

Dollar Tree (NASDAQ: DLTR) announced its plans to buy Family Dollar (NYSE: FDO) for around $8.5 billion in a cash-and-stock deal.

The transaction value of $74.50 per share represents around 23% premium to Family Dollar's closing price of $60.66 on Friday.

Equities Trading UP

Trulia (NYSE: TRLA) shares shot up 7.70 percent to $60.69 after Zillow (NASDAQ: Z) announced its plans to buy Trulia for $3.5 billion in stock.

Shares of Family Dollar Stores (NYSE: FDO) got a boost, shooting up 22.20 percent to $74.13 after Dollar Tree (NASDAQ: DLTR) announced its plans to buy Family Dollar for $8.5 billion.

Tyson Foods (NYSE: TSN) shares were also up, gaining 4.81 percent to $41.44 after the company reported upbeat third-quarter revenue and announced its plans to sell its Mexican and Brazilian chicken businesses for $575 million. The company reported weaker-than-expected quarterly net income and announced an offering of 24 million Class A
continue reading





Stocks To Watch For July 29, 2014

Courtesy of Benzinga.

Related PFE
Is a Surprise Coming for Pfizer (PFE) This Earnings Season? – Tale of the Tape
Markets Little Changed Ahead Of The Federal Reserve's Policy Decision
Week Ahead: July Jobs Report, FOMC and GDP (Fox Business)

Some of the stocks that may grab investor focus today are:

Wall Street expects Pfizer (NYSE: PFE) to report its Q2 earnings at $0.57 per share on revenue of $12.46 billion. Pfizer shares declined 0.07% to $30.08 in after-hours trading.

Twitter (NYSE: TWTR) is projected to post a Q2 loss at $0.01 per share on revenue of $283.07 million. Twitter shares gained 0.13% to $37.98 in the after-hours trading session.

Herbalife (NYSE: HLF) reported downbeat second-quarter results and issued a weak forecast for the third quarter. However, the company lifted its profit outlook for the year. Herbalife shares tumbled 11.83% to $59.50 in the after-hours trading session.

United Parcel Service (NYSE: UPS) is projected to report its Q2 earnings at $1.25 per share on revenue of $14.10 billion. UPS shares dropped 0.16% to $102.50 in after-hours trading.

Analysts are expecting American Express Company (NYSE: AXP) to have earned $1.38 per share on revenue of $8.66 billion in the second quarter. American Express shares tumbled 0.08% to close at $91.86 yesterday.

Fresh Del Monte Produce (NYSE: FDP) is estimated to report its Q2 earnings at $1.00 per share on revenue of $1.05 billion. Fresh Del Monte shares fell 0.74% to close at $29.48 yesterday.

Analysts expect Merck & Co (NYSE: MRK) to report its Q2 earnings at $0.81 per share on revenue of $10.60 billion. Merck shares rose 0.05% to $58.00 in after-hours trading.

United States Steel (NYSE: X) is projected to post a Q2 loss at $0.29 per share on revenue of $4.21 billion. United States Steel shares surged 0.43% to close at $27.84 yesterday.

Posted-In: Stocks To WatchEarnings News Guidance Pre-Market Outlook Markets Trading Ideas





FBR & Co. Announces Self Tender Offer Ro Purchase Up To One Million Shares

Courtesy of Benzinga.

Related FBRC
Top 4 Small-Cap Stocks In The Asset Management Industry With The Highest ROE
FBR & Co. Announces Results of Self-Tender Offer

FBR & Co. (Nasdaq: FBRC) today announced that it intends to commence a modified “Dutch auction” tender offer to purchase up to one million shares, or about 9.9%, of its outstanding common stock, at a price of not less than $28.00 and not more than $29.00 per share.

A modified “Dutch auction” tender offer allows stockholders to indicate how many shares and at what price(s) they wish to tender their shares within the specified price range. Based on the number of shares tendered and the prices specified by the tendering stockholders, FBR will determine the lowest price per share within the range that will allow FBR to purchase up to one million shares of its common stock, or a lower amount depending on the number of shares properly tendered and not properly withdrawn. Stockholders whose shares are purchased in the offer will receive the determined purchase price per share in cash, without interest, after the expiration of the offer period, subject to the conditions of the tender offer, including the provisions relating to proration, “odd lot” priority and conditional tenders. All shares tendered at prices higher than the purchase price will not be purchased and will be promptly returned to stockholders. The offer to purchase will not be conditioned upon any minimum number of shares being tendered; however, the tender offer will be subject to a number of other terms and conditions. Specific instructions and an explanation of the terms and conditions of the tender offer will be contained in the Offer to Purchase and related materials that FBR will file with the Securities and Exchange Commission. FBR expects to fund the purchase of shares in the tender offer with cash on hand.

FBR has retained FBR Capital Markets & Co. as the dealer manager for the tender offer and D.F. King & Co., Inc. as the information agent.

Certain Information Regarding the Tender Offer

The information in this press release describing FBR & Co.’s planned tender offer is for informational purposes only and…
continue reading





IMDZ Announces Filing Of New Lawsuit By Theravectys SA

Courtesy of Benzinga.

Related IMDZ
IPO Lookout: Lots of Action This Week, But Is Anything A Worthwhile Investment?

Immune Design (Nasdaq: IMDZ) announced today that the day after it began trading on the Nasdaq Global Market, Theravectys SA (“TVS”) filed a lawsuit against the company repeating claims that it had made in a prior lawsuit which TVS had earlier voluntarily dismissed.

TVS alleges that it has a contractual relationship with a Belgian manufacturer, Henogen, SA, which contained an exclusivity provision limiting Henogen’s ability to manufacture certain lentiviral vectors for third parties and a provision preventing Henogen from sharing or using certain TVS confidential technology related to manufacturing processes developed by TVS with or for the benefit of others. TVS asserts that the company induced Henogen to breach its exclusivity obligations by manufacturing and supplying clinical batches of lentiviral vectors to the company and seeks monetary damages, as well as injunctive relief. TVS raises claims of tortious interference with contractual relations, misappropriation of trade secrets, unfair competition and unjust enrichment.

The causes of action in this lawsuit, which was filed in the Delaware Court of Chancery, are similar to the causes of action that were contained in the prior lawsuit filed by TVS against the company in October 2013 in the United States District Court for the District of Delaware. However, the current lawsuit adds the claim of unjust enrichment. The prior lawsuit was voluntarily dismissed by TVS in April 2014.

The company previously disclosed in the prospectus related to its initial public offering that TVS may refile a suit against the company.

The company is not currently using Henogen to manufacture its lentiviral vectors for its clinical trials. The company developed its own vector manufacturing process that it previously transferred to Henogen, and did not have any knowledge of TVS’ processes. The company believes this lawsuit is without merit and intends to vigorously defend it.

Posted-In: News Legal Press Releases





Amkor Technology Guidance Tops Estimates

Courtesy of Benzinga.

Related AMKR
Stocks To Watch For June 27, 2014
Stocks To Watch For June 23, 2014

Amkor Technology (NASDAQ: AMKR) reported earnings following Monday's closing bell. The company offered stellar guidance, which moved the stock up by 4.59 percent in after-hours trading.

Analyst consensus EPS estimates for the second quarter was $0.15; Amkor reported EPS of $0.13 (excluding $0.08 impact from selling Amkor's Japanese subsidiary to J-Devices).

Amkor reported revenue of $767 million, a beat on consensus estimates of $761.4 million.

Amkor's gross margins improved to 19.6 percent, which is up from the prior year quarter of 18.5 percent. The gross margin figure could have been higher, which is why net income came in below EPS estimates.

Despite the slight miss on an adjusted basis, however, management guidance came in ahead of analyst expectations. Management offered brighter outlook, with an EPS range of $0.20 to $0.29. Analysts on a consensus basis anticipate EPS of $0.24.

EPS may come in at the higher end of the range, which is what triggered the massive move in after-hours trading.

Posted-In: Earnings News Guidance





 

Help One Of Our Own PSW Members

"Hello PSW Members –

This is a non-trading topic, but I wanted to post it during trading hours so as many eyes can see it as possible.  Feel free to contact me directly at jennifersurovy@yahoo.com with any questions.

Last fall there was some discussion on the PSW board regarding setting up a YouCaring donation page for a PSW member, Shadowfax. Since then, we have been looking into ways to help get him additional medical services and to pay down his medical debts.  After following those leads, we are ready to move ahead with the YouCaring site. (Link is posted below.)  Any help you can give will be greatly appreciated; not only to help aid in his medical bill debt, but to also show what a great community this group is.

http://www.youcaring.com/medical-fundraiser/help-get-shadowfax-out-from-the-darkness-of-medical-bills-/126743"

Thank you for you time!

 
 

Chart School

S&P 500 Snapshot: Market Hunkers Down

Courtesy of Doug Short.

This morning's release of July Consumer Confidence surprised to the upside, a finding the rather conflicts with the latest Gallup survey of Economic Confidence. But in the real world, the key headlines were about the announcement of sanctions against Russia. The S&P 500 made a shallow arc higher in the morning, hitting its intraday high shortly after the Consumer Confidence report was released. It then sold off in a couple of waves to close at its -0.45% intraday low.

The hunkering down in today's US market is probably the result of more than the Russian sanction. There's no doubt a bit of nervousness prior to tomorrow's ...



more from Chart School

Zero Hedge

Boots On The Ground In Ukraine: "I Needed To See This For Myself"

Courtesy of ZeroHedge. View original post here.

Submitted by Tyler Durden.

Submitted by Simon Black via Sovereign Man blog,

Looking back over the past ten years, I can’t even begin to describe all the experiences I’ve had in Ukraine.

For a while, I actually owned a business based here. I’ve been travelling here frequently for years. I still have many friends here. Some of our employees are based here. And Kiev is one of the cities in the world that I know best.

Yet even after all of that, I still can’t make heads or tails of this place.

Consider this: by 2004, people in Ukraine we...



more from Tyler

Phil's Favorites

Oh Yeah, About That Con Con Con

Oh Yeah, About That Con Con Con

Courtesy of Lee Adler 

As usual, the Conference Board and all the major media press release repeaters put a positive spin on the highest reading of Consumer Confidence (aka the Con Con Con) since October 2007. None of the media echo chamber reports pointed out that October 2007 was the beginning of the worst bear market in US stocks since 1973-74. So I thought it important that the issue be given a little perspective (as I did recently with the Thompson Rhoiders Michigan Con Index).

First things first, the Con Con Con is an amalgamation of the results of two survey questions presented to “consumers” (aka real people). One question asks...



more from Ilene

All About Trends

Mid-Day Update

Reminder: David is available to chat with Members, comments are found below each post.

Click here for the full report.




To learn more, sign up for David's free newsletter and receive the free report from All About Trends - "How To Outperform 90% Of Wall Street With Just $500 A Week." Tell David PSW sent you. - Ilene...

more from David

Insider Scoop

Report: IBM Rejects Offer For Chip Operations

Courtesy of Benzinga.

Related IBM Blackberry Attempts To Rebound From IBM/Apple Deal The 10 Most-Respected Corporate Brands Can the iRally Endure? (Fox Business)

International Business Machines (NYSE: IBM) rejected an offer for part of its semiconductor manufacturing operations, according to unnamed sources cited by ...



http://www.insidercow.com/ more from Insider

Option Review

Kellogg Call Options Active Ahead Of Earnings

Shares in packaged foods producer Kellogg Co. (Ticker: K) are in positive territory on Monday afternoon, trading up by roughly 0.20% at $65.48 as of 2:20 p.m. ET. Options volume on the stock is well above average levels today, with around 12,500 contracts traded on the name versus an average daily reading of around 1,700 contracts. Most of the volume is concentrated in September expiry calls, perhaps ahead of the company’s second-quarter earnings report set for release ahead of the opening bell on Thursday. Time and sales data suggests traders are snapping up calls at the Sep 67.5, 70.0 and 72.5 strikes. Volume is heaviest in the Sep 72.5 strike calls, with around 4,600 contracts traded against sizable open interest of approximately 11,800 contracts. It looks like traders paid an average premium of $0.37 per contrac...



more from Caitlin

Sabrient

Sector Detector: Bold bulls dare meek bears to take another crack

Courtesy of Sabrient Systems and Gradient Analytics

Once again, stocks have shown some inkling of weakness. But every other time for almost three years running, the bears have failed to pile on and get a real correction in gear. Will this time be different? Bulls are almost daring them to try it, putting forth their best Dirty Harry impression: “Go ahead, make my day.” Despite weak or neutral charts and moderately bullish (at best) sector rankings, the trend is definitely on the side of the bulls, not to mention the bears’ neurotic skittishness about emerging into the sunlight.

In this weekly update, I give my view of the current market environment, offer a technical analysis of the S&P 500 chart, review our weekly fundamentals-based SectorCast rankings of the ten U.S. business sectors, and then offer up some actionable trading ideas, incl...



more from Sabrient

OpTrader

Swing trading portfolio - week of July 28th, 2014

Reminder: OpTrader is available to chat with Members, comments are found below each post.

 

This post is for all our live virtual trade ideas and daily comments. Please click on "comments" below to follow our live discussion. All of our current  trades are listed in the spreadsheet below, with entry price (1/2 in and All in), and exit prices (1/3 out, 2/3 out, and All out).

We also indicate our stop, which is most of the time the "5 day moving average". All trades, unless indicated, are front-month ATM options. 

Please feel free to participate in the discussion and ask any questions you might have about this virtual portfolio, by clicking on the "comments" link right below.

To learn more about the swing trading virtual portfolio (strategy, performance, FAQ, etc.), please click here ...



more from OpTrader

Stock World Weekly

Stock World Weekly

Newsletter writers are available to chat with Members regarding topics presented in SWW in the comments below each post. 

Our weekly newsletter Stock World Weekly is ready for your enjoyment.

Read about the week ahead, trade ideas from Phil, and more. Please click here and sign in with your PSW user name and password. Or take a free trial.

We appreciate your feedback--please let us know what you think in the comment section below.  

...

more from SWW

Digital Currencies

BitLicense Part 1 - Can Poorly Thought Out Regulation Drive the US Economy Back into the Dark Ages?

Courtesy of Reggie Middleton.

An Op-Ed piece penned by Veritaseum Chief Contracts Officer, Matt Bogosian

This past weekend (despite American Airlines' best efforts), Reggie and I made it to the Second Annual North American Bitcoin Conference in Chicago. While there were some very creative (and very ambitious) ideas on how to try to realize the disruptive Bitcoin protocol, one of the predominant topics of discussion was New York Superintendent of Financial Services Benjamin Lawsky's proposed Bitcoin regulations (the BitLicense proposal) - percieved by many participants at the event as an apparent ...



more from Bitcoin

Market Shadows

Danger: Falling Prices

Danger: Falling Prices

By Dr. Paul Price of Market Shadows

 

We tried holding up stock prices but couldn’t get the job done. Market Shadows’ Virtual Value Portfolio dipped by 2% during the week but still holds on to a market-beating 8.45% gain YTD. There was no escaping the downdraft after a major Portuguese bank failed. Of all the triggers for a large selloff, I’d guess the Portuguese bank failure was pretty far down most people's list of "things to worry about." 

All three major indices gave up some ground with the Nasdaq composite taking the hardest hi...



more from Paul

Pharmboy

Biotechs & Bubbles

Reminder: Pharmboy is available to chat with Members, comments are found below each post.

Well PSW Subscribers....I am still here, barely.  From my last post a few months ago to now, nothing has changed much, but there are a few bargins out there that as investors, should be put on the watch list (again) and if so desired....buy a small amount.

First, the media is on a tear against biotechs/pharma, ripping companies for their drug prices.  Gilead's HepC drug, Sovaldi, is priced at $84K for the 12-week treatment.  Pundits were screaming bloody murder that it was a total rip off, but when one investigates the other drugs out there, and the consequences of not taking Sovaldi vs. another drug combinations, then things become clearer.  For instance, Olysio (JNJ) is about $66,000 for a 12-week treatment, but is approved for fewer types of patients AND...



more from Pharmboy

Promotions

See Live Demo Of This Google-Like Trade Algorithm

I just wanted to be sure you saw this.  There’s a ‘live’ training webinar this Thursday, March 27th at Noon or 9:00 pm ET.

If GOOGLE, the NSA, and Steve Jobs all got together in a room with the task of building a tremendously accurate trading algorithm… it wouldn’t just be any ordinary system… it’d be the greatest trading algorithm in the world.

Well, I hate to break it to you though… they never got around to building it, but my friends at Market Tamer did.

Follow this link to register for their training webinar where they’ll demonstrate the tested and proven Algorithm powered by the same technological principles that have made GOOGLE the #1 search engine on the planet!

And get this…had you done nothing b...



more from Promotions



FeedTheBull - Top Stock market and Finance Sites



About Phil:

Philip R. Davis is a founder Phil's Stock World, a stock and options trading site that teaches the art of options trading to newcomers and devises advanced strategies for expert traders...

Learn more About Phil >>


As Seen On:




About Ilene:

Ilene is editor and affiliate program coordinator for PSW. She manages the site market shadows, archives, more. Contact Ilene to learn about our affiliate and content sharing programs.

Market Shadows >>